… For a chronic disease like osteoporosis this has the following consequences: we currently
have no diagnostic method to judge whether a patient has responded well to treatment and …

… of research since patients with osteoporosis are likely to be receiving an osteoporosis drug
at the … This section will discuss the impact of different osteoporosis therapeutic agent on bone …

… and treatment of osteoporosis and of fragility fractures is increasing and new treatment
options are being developed. Few specialties require training in osteoporosis and metabolic …

… developments in the pharmacotherapy of osteoporosis with the availability of potent …
osteoporosis along with the unmet clinical needs and we discuss about the potential benefits of new …

… severe osteoporosis and in patients with low remodelling such as in glucocorticoid osteoporosis…
Nevertheless, treatment of osteoporosis is not only drug treatment: sufficient calcium and …

… It seems paradoxical that the majority of new osteoporosis treatments on the horizon also
target the osteoclast. Several of these new agents are well-advanced in clinical studies, …

… Currently, there are basically two monoclonal antibodies for osteoporosis therapy: … osteoporosis
management and in particular, on current and developing biologic drugs targeted to new …

… a decade for the treatment of patients with postmenopausal osteoporosis, Paget's disease,
and … Asymptomatic patients with secondary osteoporosis due to steroid administration or solid …

… osteoporosis have made substantial improvement in the management of patients with
osteoporosis … There are other drugs being used for the treatment of osteoporosis in some areas of …

… new drugs and approaches with improved efficacy and a vision toward a cure of osteoporosis.
… On the horizon is the potential for targeted osteoporosis therapy tailored to the patient …